SOURCE: Five Star Equities

Five Star Equities

April 04, 2012 08:20 ET

Ariad Pharmaceuticals, Inc. and Vertex Pharmaceuticals Inc. Taking Advantage of Rising Biotech Industry

Five Star Equities Provides Stock Research on Ariad Pharmaceuticals, Inc. and Vertex Pharmaceuticals Inc.

NEW YORK, NY--(Marketwire - Apr 4, 2012) - They say you never want to catch a falling knife, but what to do with a rising star such as the Biotech Industry? Biotech stocks have continued to impress investors this current year with the Biotech Industry striking a 30 percent gain year-to-date, according to the Biotech Index (BTK). Five Star Equities examines the outlook for companies in the Biotechnology Industry and provides investment research on Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).

Access to the full company reports can be found at:

"I think we are beginning to see signs of life amongst biotechs, with new products coming to market that are gaining traction. Innovation is a great way to get paid, in any market environment or regulatory environment," says Marshall Gordon, health care analyst at Clear Bridge Advisors. "If you look at the pharmaceutical industry today, they are desperate for products, and the way to get those is by buying biotech," he says.

Five Star Equities releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

Ariad Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 1 against the use of the investigational agent ridaforolimus as maintenance therapy for patients with metastatic soft-tissue sarcoma or bone sarcoma whose disease has not progressed after at least four cycles of chemotherapy.

Vertex Pharmaceuticals Inc. announced interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with genotype 1 hepatitis C virus and human immunodeficiency virus (HIV). Data showed 74% (28/38) of patients who were treated with INCIVEK (in-SEE-veck) combination therapy had undetectable hepatitis C virus (HCV RNA) 12 weeks after the end of all study treatment (SVR12) compared to 45% (10/22) who were treated with pegylated-interferon and ribavirin alone.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

Contact Information